Please ensure Javascript is enabled for purposes of website accessibility

Why C.R. Bard Is Poised to Outperform

By Brian D. Pacampara, CFA - Apr 25, 2013 at 10:32AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Market-trouncing returns could be written in this 5-Star.

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical device company C.R. Bard (BCR) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at C.R. Bard and see what CAPS investors are saying about the stock right now.

C.R. Bard facts

 

 

Headquarters (founded)

Murray Hill, N.J. (1907)

Market Cap

$8.1 billion

Industry

Healthcare equipment

Trailing-12-Month Revenue

$3.0 billion

Management

Chairman/CEO Timothy Ring

President/COO John Weiland

Return on Equity (average, past 3 years)

23%

Cash/Debt

$896.3 million / $1.4 billion

Dividend Yield

0.8%

Competitors

Boston Scientific

Johnson & Johnson 

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 97% of the 279 members who have rated C.R. Bard believe the stock will outperform the S&P 500 going forward.

Earlier this week, one of those Fools, All-Star JohnCLeven, succinctly summed up the C.R. Bard bull case for our community:

[C.R. Bard] has been on my radar for a while. [C.R. Bard] exhibits many of the characteristics that I find appealing in a business including: high returns on capital and equity, consistent growth in earnings and free cash flows, share buybacks, and a solid balance sheet.

[C.R. Bard] has a solid position within the medical device industry, and I believe that probability is very high that [C.R. Bard] will continue to create significant value over the next 5-10 years, and probably much longer. At today's 6.8% free cash flow yield, this high-quality business should outperform in the long run.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

C. R. Bard, Inc. Stock Quote
C. R. Bard, Inc.
BCR

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
356%
 
S&P 500 Returns
124%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.